Free Trial!
Today’s Best Stocks To Trade! Click Here
Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts.
LANTIS LASER INCORPORATED (OTC: LLSR)
Detailed Quote: http://www.otcpicks.com/quotes/LLSR.php
Company Profile: http://www.otcpicks.com/lantis-laser/lantis-laser-2.htm Lantis Laser was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); LightLab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser, visit www.lantislaser.com.
LLSR News:
July 22 - Lantis' OCT Dental Imaging System Uses Fast-Growing, Light-Based Technology
Research Publication Projects OCT Market to Top $800 Million by 2012
Lantis Laser Inc.'s (OTC: LLSR | Quote | Chart | News | PowerRating) (www.lantislaser.com) OCT Dental Imaging System, a diagnostic aid for the early detection of decay and microstructural defects, deploys optical coherence tomography (OCT), a novel light-based, high-resolution, diagnostic imaging technology.
According to Optical Coherence Tomography - Technology, Markets, and Applications: 2008-2012, the first market research report to quantify this rapidly expanding field, the global market for OCT systems is currently around $200 million and growing at an annual rate of 34%. This trend is expected to continue for the next several years, with revenues topping $800 million by 2012.(1)
OCT is fast becoming the most successful optics technology to be applied in the medical field. As it a light-based technology, unlike x-ray, there is no radiation. It is generally considered to be the sixth major diagnostic imaging technology after x-ray, ultrasound, CT scan, MRI and PET scan. The significance of OCT technology is evidenced by the number of bio-medical applications under research and development and the large increase in the number of OCT publications over the last several years.
The increasing interest in OCT in the medical field, of which dentistry is the largest sub-group comprising 140,000 dentists practicing in 100,000 offices and clinics in the U.S. alone, has grown significantly over the last few years as is evidenced by the number of research publications. OCT applications research and publications are occurring over a wide area of medical disciplines, including ophthalmology, cardiovascular imaging, dermatology, optical biopsies, cancer detection, urology, and ear, nose and throat.
OCT was first discovered and researched in the early 1990s at the Massachusetts Institute of Technology and commercialized in ophthalmology, where it has been widely embraced, by Carl Zeiss Meditec. In a press release in November 2006 Carl Zeiss announced that they had sold 6000 Stratus( systems since its introduction in 2002. Cardiovascular imaging and dentistry are expected to be the next major clinical applications of OCT technology.
Dr Craig Gimbel, Vice-President Clinical Affairs at Lantis, commented that, "OCT is ideally suited for use in dentistry as it provides high-resolution, chairside diagnostic imaging, in real time. Lantis' small handpiece scanner which employs patented state-of-the art MEMS technology, allows easy access to all parts of the oral cavity and ensures a user friendly interface with the OCT System." Dr. Gimbel went on to say that he envisages that the many clinical applications of OCT in dentistry augurs well for OCT to be successfully embraced by the dental profession. Market introduction of Lantis' OCT Dental Imaging System is projected for the first quarter of 2009. The OCT System enables dentists to detect decay and microstructural defects at an early stage and to deploy minimally invasive treatment.
(1) G. Smolka, Optical Coherence Tomograph: Technology, Markets, and Applications 2008-2012, PennWell Corp., www.BioOpticsWorld.com/resourcecenter/OCTreport.html.
RESPONSE BIOMEDICAL CORPORATION (OTCBB: RPBIF | Quote | Chart | News | PowerRating) "Up 21.62% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/RPBIF.php
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP Platform for clinical and environmental applications. RAMP represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use. The RAMP system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP clinical tests are commercially available for the early detection of heart attack and congestive heart failure. In late 2006, the Company formed a strategic alliance with 3M Company to commercialize rapid infectious disease tests and in 2008 entered into a strategic alliance with Roche Diagnostics to commercialize cardiovascular POC tests worldwide. In the non-clinical market, RAMP Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response has achieved CE Marking for its clinical products and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000. Response Biomedical is a publicly traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, visit www.responsebio.com.
RPBIF News:
July 22 - Response Biomedical Receives US FDA Clearance for RAMP NT-proBNP Test for Diagnosis of Heart Failure
Response Biomedical Corporation (OTCBB: RPBIF | Quote | Chart | News | PowerRating) (TSX: RBM) announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to market the RAMP NT-proBNP Test as an aid to the rapid diagnosis of heart failure (HF).
"NT-proBNP is emerging as a superior marker for the diagnosis of heart failure," said S. Wayne Kay, Chief Executive Officer. "The introduction of the point-of-care RAMP NT-proBNP Test is a significant advance as it supports the drive for speed and accuracy of diagnosis for patients presenting in emergency rooms and for early detection in ambulatory care. Because the performance of our RAMP NT-proBNP Test is clinically concordant with that of the Roche Elecsys proBNP Test, a hospital can have standardized clinical decision points for NT-proBNP in both their emergency rooms and central laboratories. The addition of the innovative NT-proBNP Test expands the menu of the RAMP200 analyzer for the rapid assessment of patients with symptoms of cardiovascular disease."
Dr. James L. Januzzi, the Director of the Coronary Care Unit at Massachusetts General Hospital expressed his enthusiasm for the imminent introduction of the RAMP NT-proBNP Test. "As the first full range point-of-care assay for NT-proBNP, the RAMP Test will present a major step forward for rapid and confident diagnosis of heart failure using this important blood test. Clinical trials, including studies done at the Massachusetts General Hospital, have shown that the RAMP result can be used interchangeably with results from automated NT-proBNP Tests done in the hospital laboratory. This harmony between the RAMP and the automated NT-proBNP Tests represents a huge advantage over most point-of-care BNP assays, which have disappointing harmony with their automated counterparts."
Response Biomedical recently announced a partnership granting rights to Roche Diagnostics, a world leader in clinical diagnostics, to market its line of cardiovascular point-of-care (POC) tests. Roche Diagnostics' comprehensive sales and marketing infrastructure allows for broad worldwide penetration of Response Biomedical's cardiovascular line.
ABOUT HF
HF impedes the ability of the heart to pump blood at a rate sufficient to support the body's vital needs. HF affects nearly 17 million people worldwide, and is the single most frequent cause of hospitalization in people over 65 years. The initial diagnosis of HF is problematic as symptoms can be associated with other pathologies such as respiratory disease and the secondary effects of obesity. According to the Canadian Heart and Stroke Foundation, doctors estimate that there are 200,000 - 300,000 Canadians with heart failure. Since 1970, the number of Canadians dying from congestive heart failure has increased sixty per cent. According to the American Heart Association, approximately five million Americans are currently afflicted with HF and 550,000 new cases are diagnosed each year. The prevalence of HF is expected to continue increasing due to the aging population and improved survival rates of patients with other cardiovascular diseases.
ABOUT NT-PROBNP
NT-proBNP is widely recognized as a definitive marker for the diagnosis of HF. NT-proBNP is cleaved from the precursor peptide proBNP in quantities directly proportional to its biologically active counterpart BNP and in close correlation with the severity of heart failure. BNP is secreted primarily from the left ventricle in response to pressure overload and regulates blood pressure, electrolyte balance and fluid volume. BNP acts to reduce the pressure overload. Elevated levels of NT-proBNP indicate the presence of heart failure, and provide physicians with an important diagnostic tool in the early detection and management of HF. Independent published studies show that NT-proBNP is also valuable for: risk stratification of patients with stable coronary heart disease, as a prognostic marker across the entire spectrum of cardiovascular diseases, potentially detecting early stages of HF in the absence of clinically obvious symptoms, and for the assessment of prognosis for patients with HF and for patients who have previously had a myocardial infarction.
INVICTA GROUP INCORPORATED (OTCBB: IVIT | Quote | Chart | News | PowerRating) "Up 50.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/IVIT.php
Invicta Group Inc. is an Internet Media Company that specializes in the Travel and Entertainment Industry. The company has a subsidiary that uses the Internet as their media to generate revenues: Travel Hot Link links travel enthusiasts with products to fulfill their travel and entertainment needs. Travel Hot Link sells its Internet database of 25 million travel enthusiasts to Travel Suppliers that want to promote their discounted travel products: airline tickets, hotel rooms, tour packages, rental cars, cruise cabins, and more on the Internet 24/7. There are over 50 websites but the main 6 are: www.Travelhotlink.com, www.Cruisehotlink.com, www.Airhotlink.com, www.Hotelhotlink.net, www.Autohotlink.net and www.Tickethotlink.com.
IVIT News:
July 21 - ICP Solar Enters into Sales Contract with Nissan for New OEM Solar Charger
Projected Revenues Expected to Exceed $250,000 Annually
Invicta Group Inc. (OTCBB: IVIT | Quote | Chart | News | PowerRating) announces the launch of www.TicketHotLink.com, a new division to offer and process online ticket sales. Invicta group Inc. is blending its online traffic from over 50 websites, with its 25,000,000-email database, and the marketing power of its new marketing firm IMAGE Worldwide, Inc. (OTC: IMGW) to offer a new online service. This year the Company expects revenues of around $25,000; $100,000 in 2009 and $250,000 in 2010.
www.TicketHotLink.com allows online users to search 1000s of venues for 100,000s of tickets for sporting events, concerts, and other special events.
Invicta's CEO Paul Sorkin said, "Ticket sales offer a perfect tie-in for our online users looking for travel packages that may include airline tickets, hotel reservations, car rentals, and now tickets to that special event. We are going to continue to launch new divisions that will add to our bottom line over the coming months; with all of our divisions, we expect to see healthy growth over the coming months and years."
ABOUT IMAGE WORLDWIDE, INC.
IMAGE Worldwide, Inc. (OTC: IMGW) is a full service interactive multimedia marketing and advertising agency. IMAGE is vertically integrated with properties including a concert/nightclub venue, fashion/entertainment magazine, high-end direct mailing book, IT solutions company, along with other promotional and marketing companies. IMAGE utilizes a combination of different forms of media and promotions to help clients showcase and market their IMAGE in print, Internet, event planning, radio, and TV.
FRANKLIN MINING INCORPORATED (OTC: FMNJ | Quote | Chart | News | PowerRating) "Up 14.29% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/FMNJ.php
Franklin Mining, Inc. primarily has mining and energy interests in the United States and Bolivia. It also holds various energy interests for the development and construction of gas-to-liquid facilities in Argentina. Franklin Mining, Inc. was formerly known was WCM Capital, Inc. The company was founded in 1864 and is headquartered in San Antonio, Texas with additional offices in La Paz and Santa Cruz, Bolivia and Buenos Aires, Argentina.
FMNJ News:
July 21 - Franklin CEO Returns to Bolivia; SGS of Canada's Lab Analysis of Escala Mine Indicates Significant Silver and Zinc Content
Franklin Mining, Inc. (OTC: FMNJ | Quote | Chart | News | PowerRating) (Frankfurt: FMJ.F) Chairman and President William A. Petty has returned to Bolivia to review and discuss the Escala's laboratory analysis and metallurgy reports prior to a full release of the mine's mineral content.
"I am encouraged by the reports and analysis received from the SGS Laboratory in Ontario, Canada. The 250 samples taken from Escala in June 2008, packaged and shipped following the Colorado School of Mines' prescribed procedures, are indicating significant silver and zinc content." Mr. Petty continued, "Even though we've not yet fully completed the review process, I have begun preparing a recommendation for approval of further capital investment in our Escala operation."
Franklin's Escala managers, geologist and engineer will review the reports this week and discuss them with Fernando Infante, Executive Vice President, and Howard Dunn, Vice President of Operations, International Mining, before releasing the full report.
WIFIMED HOLDINGS CORPORATION (OTCBB: WIFM | Quote | Chart | News | PowerRating) "Up 25.00% in morning trading" Detailed Quote: http://www.otcpicks.com/quotes/WIFM.php WiFiMed Holdings Company, Inc., through its subsidiaries, WiFiMed, Inc. and EncounterPRO Healthcare Resources, Inc., develops and sells electronic health record software, and related services and computer hardware to medical practices. The company offers Tablet MD EHR, a software solution, which manages patient medical information, consultation notes, prescriptions, and other components of the medical chart. Its solutions help physicians and health care providers to manage patient workflow; and reduce medical errors, documentation time, overhead, and time spent filing insurance claims. WiFiMed Holdings also offers EncounterPRO EHR, an electronic health record solution. The company was founded in 2002 and is based in Atlanta, Georgia.
WIFM News:
July 22 - EncounterPRO Healthcare Resources Continues Aggressive Growth with Signing of Tots & Teens Pediatrics as Newest Client
WiFiMed Holdings Company, Inc. (OTCBB: WIFM | Quote | Chart | News | PowerRating) ("WiFiMed Holdings"), a leading provider of physician workflow solutions, announced that its wholly owned subsidiary, EncounterPRO Healthcare Resources, Inc., has signed Tots and Teens Pediatrics as their newest client. Located near Corpus Christi, TX, Tots and Teens Pediatrics is a four provider group that was introduced to the EncounterPRO system through Driscoll Children's Hospital. Tots and Teens Pediatrics represents the fourth practice that has signed with EncounterPRO through their direct dealings with Driscoll Children's Hospital.
EncounterPRO Healthcare Resources' current product line is well established and widely used by Pediatric, Family Practice and Internal Medicine physicians and their staff. The EncounterPRO EHR is a highly valuable tool for physicians and serves to manage the patient encounter process within the practice. By allowing practices to function at optimal conditions, the EncounterPRO EHR software enhances patient satisfaction as well as practice profitability. On the whole, the EncounterPRO EHR is able to improve the clinical experience for patients and practitioners alike.
"Electronic health record systems are no longer the technology of the future; they are the necessity of today," stated Gregory Vacca, Chief Executive Officer of WiFiMed Holdings. "EncounterPRO EHR is a user friendly and efficient system that will save physicians money, help practices organize their record filing systems and expedite prescription processing. We look forward to working with our new clients, Tots and Teens Pediatrics, to ensure that their EncounterPRO experience is everything they expect and more."
If you would like to be added to WiFiMed Holdings' investor email list please contact Zack Noory with Nexus Investor Relations at znoory@nexusir-online.com.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated two hundred thousand restricted 144 shares from a third party for LLSR advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
